ClinicalTrials.gg
CompletedNCT05224037OGIG-01-22-LFUpdated Apr 11, 2023

Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch

An interventional study of iLivTouch in Chronic Liver Disease, Liver Fibrosis and Liver Steatoses, sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-11.

Sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky Medical Technologies Co., China) in patients with chronic liver diseases.

Read the detailed description

This is prospective comparative trial to assess diagnostic characteristics of non-invasive methods of liver fibrosis and steatosis assessment based on the measurement of liver stiffness. The null hypothesis is that novel device, iLivTouch FT100/FT200 and standard probe allows to obtain similar results of liver stiffness and controlled attenuation parameter compared to FibroScan 530 and probes M+ and XL+ in patients with chronic liver diseases. According to the study protocol, standard examination will be performed to eligible subjects on the same day with the use of both devices. At least 10 measurements will be performed with the use of each device to each subject after overnight fasting. The medians of liver stiffness and controlled attenuation parameter measurements, their interquartile range, success rate of measurements and related interpretations of the results (grades of liver fibrosis and steatosis) will be compared. To assess the variability of the results, demographic data (age, biological sex, ethnicity) will be collected; weight and height of the subjects will be measured on the day of examination. Medical history of the subjects will be examined to extract data, confirming the presence of chronic liver diseases and ensure eligibility.

02

Conditions studied

  • Chronic Liver Disease
  • Liver Fibrosis
  • Liver Steatoses

Keywords

  • ilivtouch
  • fibroscan
  • liver stiffness measurement
  • controlled attenuation parameter
  • non-alcoholic fatty liver disease
  • liver steatosis
03

In context

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

This study's enrollment of 100 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • willingness to participate on the basis of the signed form;
  • availability of the medical records

Exclusion criteria

Exclusion Criteria:

  • pregnancy and breastfeeding;
  • narrow intercostal spaces making standard examination of the liver stiffness possible;
  • extreme obesity, in cases when amount of the fat tissue in right lower part of chest makes impossible to perform measurements;
  • ascites;
  • focal lesions of the liver (including, but not limited to liver cancer or of cancer regardless of their origin, parasitic invasions, cysts) in projection of the measurements;
  • impossibility to perform evaluation with both devices due to any reasons;
  • any health-related conditions of a subject that put him/her at risk in case the procedures required per study protocol are performed or making him/her ineligible on the discretion of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Study group

    This is a single-arm study. All the participants will undergo examinations with 2 devices

    Diagnostic Test: iLivTouch

Interventions

  • Diagnostic testiLivTouch

    Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day

    Also known as: FibroScan

06

What researchers measure

Primary outcomes

  1. Liver stiffness

    Single assessment (Median by at least 10 measurements) of the liver stiffness in kilo pascals will be performed during examination of the subject

    Time frame: Study day 1

  2. Controlled attenuation parameter

    Single assessment (Median by at least 10 measurements) of the controlled attenuation parameter in kilo pascals will be performed during examination of the subject

    Time frame: Study day 1

Secondary outcomes

  1. Interquartile range of liver stiffness

    Single assessment (interquartile range by at least 10 measurements) of the liver stiffness in kilo pascals will be performed during examination of the subject

    Time frame: Study day 1

  2. Interquartile range of the controlled attenuation parameter

    Single assessment of interquartile range of the controlled attenuation parameter (by at least 10 measurements) in kilo pascals will be performed during examination of the subject

    Time frame: Study day 1

  3. Success rate

    Success rate (a quotient of division of number of successful measurement on the total of number of measurements performed during examination of a subject) with iLivTouch and Fibroscan

    Time frame: Study day 1

  4. Stage of liver fibrosis

    stage of liver fibrosis according to the liver stiffness and manufacturers instruction on the interpretation of the results of iLivTouch and FibroScan

    Time frame: Study day 1

  5. Stage of steatosis of the liver

    stage of liver fibrosis according to the measurement of the controlled attenuation parameter obtained during examination of a subject and manufacturers instruction on the interpretation of the results of iLivTouch and FibroScan

    Time frame: Study day 1

07

Study locations

1 site
  • Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
    Moscow, 115446, Russian Federation
08

References and documents

Individual participant data

Plan to share: Yes — depersonalised individual participants data may be shared upon reasonable request to the principal investigator after study completion

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: after study completion

Access criteria: request to the investigator

Data sharing details ↗ · ion.ru

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Mar 2022, 1 month.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's 1 month is below that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Feb 4, 2022
StartActual
Jan 21, 2022
Primary completionActual
Mar 15, 2022
CompletionActual
Dec 31, 2022
Last update
Apr 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05224037
Lead sponsor
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
Responsible party
Sergey Morozov (Leading researcher, Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology) — Principal investigator
First posted
Feb 4, 2022
Start date
Jan 21, 2022
Primary completion
Mar 15, 2022
Completion
Dec 31, 2022
Last update
Apr 11, 2023

Study contacts

Vasily Isakov, Professor
study chair · Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion